Zealand Pharma A/S (OTCMKTS:ZLDPF) Releases Earnings Results, Beats Estimates By $0.19 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) released its earnings results on Thursday. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.19, Zacks reports. Zealand Pharma A/S had a negative return on equity of 18.49% and a negative net margin of 1,375.16%.

Zealand Pharma A/S Stock Performance

ZLDPF remained flat at $108.30 on Thursday. The company had a trading volume of 5 shares, compared to its average volume of 330. Zealand Pharma A/S has a fifty-two week low of $67.58 and a fifty-two week high of $141.74. The company has a market cap of $7.69 billion, a P/E ratio of -44.57 and a beta of 0.88. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03. The company has a 50 day moving average price of $102.18 and a two-hundred day moving average price of $113.71.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ZLDPF. JPMorgan Chase & Co. started coverage on Zealand Pharma A/S in a research report on Friday, November 8th. They issued an “overweight” rating on the stock. Cantor Fitzgerald upgraded Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, January 21st.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.